Promising 85% Response: Ru-D Regimen Shows Hope for Adults with HLH
Blood Journals Portfolio recently shared a post on X:
”The Ru-D regimen was well tolerated, resulting in OS rates of 85.7%, 67.9%, and 53.6% at 2 months, 6 months, and 2 years, respectively.”
Read the full article here.
The recently published article ”Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China” by De Zhou et al. in Blood sheds light on the possible positive results from combination of Ruxolitinib with Dexamethasone in HLH patients.
A phase 2 trial of the Ru-D regimen—ruxolitinib combined with dexamethasone—showed promising results in adults newly diagnosed with HLH of unknown triggers.
Among 28 patients, the overall response rate was 85.7%, with a 2-month overall survival rate of 85.7% and favorable 2-year survival in non-lymphoma-associated HLH cases.
The Ru-D regimen was well tolerated, supporting further investigation in a phase 3 trial.
Latest scientific advancements in hematology featured in Hemostasis Today.
-
Jul 18, 2025, 12:18NBCA Hosts PEP Talk with Dr. Parks on Aging and Blood Clots
-
Jul 18, 2025, 12:14WFH Shares Powerful Patient Story on Access to Bleeding Disorders Treatment
-
Jul 18, 2025, 11:53HTRS Shines Spotlight on Faculty Powering the Future of Hemostasis and Thrombosis
-
Jul 16, 2025, 17:23ISTH 2025 Spotlight: HOPE-B Trial Highlights Sustained Efficacy of Gene Therapy for Hemophilia B
-
Jul 16, 2025, 15:00Together with Dr. Bethany Samuelson Bannow – Let’s Keep Hematology Moving Forward
-
Jul 19, 2025, 17:16Promising 85% Response: Ru-D Regimen Shows Hope for Adults with HLH
-
Jul 19, 2025, 16:16A Potential Link to Recurrent Pregnancy Loss: Monoclonal Anti-PF4 Antibodies' Role
-
Jul 19, 2025, 15:2115% Recanalization Rate During Transfer in Basilar Artery Occlusion: A Missed Opportunity?
-
Jul 18, 2025, 18:54New Issue Alert! Advances in Stroke: Vascular and Interventional Neurology 2025
-
Jul 16, 2025, 11:06Why Pain Feels Different for Everyone - The Guardian
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Jul 13, 2025, 15:35World’s First Liver Transplant for Plasminogen Deficiency Performed at KFSHRC
-
Jul 7, 2025, 17:08Detecting Anti-Drug Antibodies to Emicizumab: A French Center’s Remarkable Experience
-
Jul 16, 2025, 10:24Salma Ismail: Honored to Be Invited By the EHA2025 as Part of Their Lighting the Flame Program
-
Jul 15, 2025, 17:002022 Chemistry Laureate Carolyn Bertozzi Shares Inspiring Advice for Young Scientists
-
Jul 15, 2025, 16:42A 200+ Year Historical Review of Women and Hemophilia: Shifting Perspectives
-
Jul 10, 2025, 18:25Dr. Carol Kasper: Honoring the Legacy
-
Jul 8, 2025, 08:26ASH and HVO Collaborate to Expand Hematology Training in LMICs